71 results about "Kidney stone" patented technology

The invention belongs to the field of biomedicine, and particularly relates to application of CRYL1 protein in preparation of a product for evaluation, diagnosis or auxiliary diagnosis of postoperative recurrence risk of calcium oxalate kidney stone combined with renal nipple calcium spot, and the sequence of the CRYL1 protein is shown as SEQ ID NO.1. The invention discovers that the expression of the CRYL1 protein in renal tubules and collecting tube cells of renal papillary calcium spot tissues is reduced for the first time, and tests prove that the urine CRYL1 protein is a predictive factor and a predictive marker for postoperative recurrence of a patient with CaOx kidney stone combined with renal papillary calcium spot. The CRYL1 protein detection kit is further researched and developed to be used for detecting or evaluating the postoperative recurrence risk of patients suffering from CaOx kidney stone combined with renal nipple calcium spots, personalized follow-up visit and prevention schemes of the patients are promoted, and the CRYL1 protein detection kit has huge clinical application prospects.

Disclosed herein are systems, devices, and methods for the removal of objects from the body. The device may be a urethral catheter configured to aspirate kidney stones from the urinary tract through one or more aspiration ports at the distal face or along a lateral side of the catheter. The catheter may include one or more irrigation ports at the distal face or along the lateral side of the catheter for dislodging kidney stones. The device may be steerable. The spatial arrangement of the one or more irrigation ports with respect to the one or more aspiration ports may vary. The device may include an irrigation tube and / or a shield member configured to spatially confine the kidney stones adjacent the catheter. Various temporal patterns of aspiration and irrigation are disclosed for optimizing removal of kidney stones.

Disclosed in the present invention is an siRNA for inhibiting the expression of a urate transporter 1 (URAT1) gene in human cells. In the present invention, a plurality of siRNAs capable of inhibiting URAT1 expression are obtained by screening, and on this basis, appropriate modifications are performed to obtain sequences with improved target silencing ability. Drugs with the siRNAs as active ingredients are expected to be clinically applicable in the prevention and treatment of diseases related to the URAT1 target, such as gout, hyperuricemia, gouty arthritis and renal calculi.

The present application provides a system for guided removal of particulate matter from a body of a subject, in particular a system for removing a plurality of small stone fragments from a kidney of a subject. The system comprises a ureter kidney access sheath, a kidney perfusion catheter, an imaging device and a double-acting pumping device. The ureteral kidney access sheath includes a fluid discharge port connected to a double-acting pumping device. The kidney perfusion catheter includes a fluid inlet port connected to the double-acting pumping device. Also disclosed is a method for removing particulate matter from a kidney of a subject, the method comprising using the system.

A medical device for retrieval of kidney stone fragments from a urinary tract is provided. The medical device has a plurality of magnets arranged within a flexible sheath forming a flexible wire. The magnets are magnetically attached end-to-end and arranged with their magnetic polarities alternating in direction. The magnetization direction of each of the magnets is orthogonal to the length axis of the flexible wire. A removable inner stylet is situated within the flexible sheath allowing for modifiable flexibility of the wire. The medical device is dimensioned to be introduced into the urinary tract and standard endoscopic devices. The medical device is further dimensioned to allow for the wire with magnetically attached stone fragments to be retrieved from the urinary tract. The magnetic field along the length axis is sufficient to attract to the surface of the flexible wire superparamagnetic nanoparticles which have bound themselves to kidney stone fragments.

Implementations of the present disclosure generally relate to medical aspiration devices and their methods of use. In some cases, the devices are configured to create a vacuum to capture and / or immobilize a solid deposit at a location internal to a subject. Such configurations may be useful, for example, for removing intact kidney stones small enough to pass through the ureter. In some cases, the devices further include an ablation instrument. Such devices may be useful, for example, for ablating larger solid deposits into a plurality of smaller particles at a location internal to the subject (e.g., ablating kidney stones that are too large to pass through the ureter). In some cases, the vacuum created by the devices is used to remove the plurality of smaller particles from the location internal to the subject.

The subject matter described herein includes a kidney stone suction tube device and related methods of use. According to one example, the disclosed subject matter includes a suction tube device comprising a flexible tubing element comprising a modified suction tube portion characterized as having U-shaped hollow lumen channel and an intra-renal portion characterized as having circular shaped lumen channel. The intra-renal portion of the suction tube device further includes a collection cylinder section configured for storing kidney stone fragments. In addition, the connection of the modified suction tube portion and the collection cylinder section includes a mesh filter element configured to prevent admittance of kidney stones into the modified suction tube portion of the flexible tubing element.

Implementations of the present disclosure generally relate to medical aspiration devices and their methods of use. In some cases, the devices are configured to create a vacuum to capture and / or immobilize a solid deposit at a location internal to a subject. Such configurations may be useful, for example, for removing intact kidney stones small enough to pass through the ureter. In some cases, the devices further include an ablation instrument. Such devices may be useful, for example, for ablating larger solid deposits into a plurality of smaller particles at a location internal to the subject (e.g., ablating kidney stones that are too large to pass through the ureter). In some cases, the vacuum created by the devices is used to remove the plurality of smaller particles from the location internal to the subject.

Embodiments of the present disclosure generally relate to medical aspiration devices and methods of use thereof. In some cases, the devices are configured to generate a vacuum to capture and / or immobilize solid deposits at a location within a subject. Such configurations can be useful, for example, for removing intact kidney stones that are small enough to pass through a ureter. In some cases, the devices further include ablation instruments. Such devices can be useful, for example, for ablating larger solid deposits into a plurality of smaller particles at a location within a subject (e.g., ablating a kidney stone that is too large to pass through a ureter). In some cases, the vacuum generated by the devices is used to remove the plurality of smaller particles from the location within the subject.

The invention relates to a triazole derivative and an application thereof in medicine, in particular to a compound shown in a general formula (I) or a stereoisomer, a tautomer, a deuterated compound, a solvate, a prodrug, a metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate and a preparation method thereof, and an application of the triazole derivative in preparation of medicines for treating kidney stone, recurrent kidney stone, renal calculus and the like. The invention also relates to application of the pharmaceutical composition in drugs for treating type I primary hyperoxaluria (PH). # imgabs0 #

Disclosed herein are systems, devices, and methods for the removal of objects from the body. The device may be a urethral catheter configured to aspirate kidney stones from the urinary tract through one or more aspiration ports at the distal face or along a lateral side of the catheter. The catheter may include one or more irrigation ports at the distal face or along the lateral side of the catheter for dislodging kidney stones. The device may be steerable. The spatial arrangement of the one or more irrigation ports with respect to the one or more aspiration ports may vary. The device may include an irrigation tube and / or a shield member configured to spatially confine the kidney stones adjacent the catheter. Various temporal patterns of aspiration and irrigation are disclosed for optimizing removal of kidney stones.

The invention discloses an application of a fibroblast growth factor 2 in preparation of a medicine for preventing and / or treating calcium oxalate kidney stone, and breaks through the technical prejudice that FGF-2 mainly promotes renal fibrosis in the prior art. It is found and proved for the first time that exogenous supplement FGF-2 can play a significant therapeutic effect in a calcium oxalate kidney stone model. Animal experiments prove that through intraperitoneal injection of FGF-2 (0.1 mg / kg / day), calcium salt crystal deposition in kidney tissue can be effectively reduced (Von Kossa dyeing verification), structural damage of renal tubular epithelial cells is relieved, inflammatory response is inhibited (HE dyeing verification), and meanwhile the serum creatinine and urea nitrogen level is remarkably improved. The invention provides a brand new molecular target and drug strategy for treatment of kidney stone, can be used as an effective auxiliary scheme of the existing physical lithotripsy technology, and reduces the risk of stone residue and recurrence.

This application discloses a biomarker for calcium oxalate kidney stones and its application, relating to the field of pharmaceutical technology. Specifically, it proposes a biomarker for calcium oxalate kidney stones, namely isolithocholic acid. It reveals that isolithocholic acid directly targets and activates the PARP1 protein, inducing parthanatos in renal tubular epithelial cells, leading to cell damage and a microenvironment conducive to crystal adhesion, ultimately driving kidney stone formation. Isolithocholic acid is specifically elevated in feces, serum, kidney, and urine in a calcium oxalate kidney stone model, and its spatial localization is associated with areas of renal tubular damage, indicating its high relevance as a diagnostic or risk warning biomarker.

This invention belongs to the field of biomedical technology, specifically disclosing the use of neuron-derived neurotrophic factors in the preparation of drugs for the prevention and treatment of kidney stones. Using a glyoxylate-induced mouse model of kidney calcium deposition, this invention demonstrates that neuron-derived neurotrophic factors can significantly reduce kidney calcium deposition, alleviate renal tubular structural damage, and improve renal function indicators. This achieves comprehensive intervention in the entire process of kidney stone disease, from crystal formation to tissue damage to functional abnormalities, exhibiting superior technical effects compared to single stone-dissolving or stone-expelling strategies, and possesses significant application value and clinical translational potential.

The invention belongs to the field of biomedicine, and relates to application of Herbacetin in prevention of renal nipple calcium spot related calcium oxalate kidney stone. The invention relates to an application of Herbacetin or pharmaceutically acceptable salt, ester, solvate, crystal form or prodrug thereof in preparation of a reagent for preventing renal papillary calcium spot related calcium oxalate kidney stone, the Herbacetin has the following structural formula: the Herbacetin is used for preventing and treating renal interstitial calcium salt deposition and Randall plaque progress for the first time, and experiments prove that the Herbacetin can be used for preventing and treating renal interstitial calcium salt deposition and Randall plaque progress. Herbacetin has the effect of inhibiting the inflammation induction of renal interstitial hydroxyapatite crystals on fibroblasts, and has the application prospect of improving the immune microenvironment of renal interstitial and the deposition of renal interstitial calcium salt.

The application provides rhamnogalacturonan I, a pharmaceutical composition and a preparation method and application thereof, and belongs to the field of biotechnology and chemistry.A new rhamnogalacturonan I is separated from polygonum aviculare, and the structure and performance of the rhamnogalacturonan I are characterized.It is found that the new rhamnogalacturonan I can play an anti-kidney stone role.The new rhamnogalacturonan I has important clinical significance and application prospect in preparation of a medicine for preventing and / or treating kidney stones.

According to the invention, a human renal cortex proximal tubule epithelial cell HK2-CaOx model and a rat kidney stone animal model are adopted, differential modified proteins are analyzed and verified through a protein modification omics technology, and key factors and key sites of lactic acid modification participating in regulation and control of kidney stone generation are identified; single cell sequencing is combined with space transcriptome analysis, identification and subdivision of kidney cell subgroups, and differential expression ligand and receptor pairs and key signal channels of macrophages and renal tubular epithelial cells are analyzed through cell communication. On the basis, the key function of the LDHB protein lactic acid modification site K156 in the kidney stone progress process is identified, and a new molecular marker and a treatment target are provided for early diagnosis of kidney stone and intervention of kidney stone.

1. Name of the designed product: label (wolf kidney stone). 2. Use of the designed product: label for packaging container. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo that best shows the design points: main view of component 1. 5. The designed product is a thin product, and other views of component 1 and component 2 are omitted.

Implementations of the present disclosure generally relate to medical aspiration devices and their methods of use. In some cases, the devices are configured to create a vacuum to capture and / or immobilize a solid deposit at a location internal to a subject. Such configurations may be useful, for example, for removing intact kidney stones small enough to pass through the ureter. In some cases, the devices further include an ablation instrument. Such devices may be useful, for example, for ablating larger solid deposits into a plurality of smaller particles at a location internal to the subject (e.g., ablating kidney stones that are too large to pass through the ureter). In some cases, the vacuum created by the devices is used to remove the plurality of smaller particles from the location internal to the subject.

Implementations of the present disclosure generally relate to medical aspiration devices and their methods of use. In some cases, the devices are configured to create a vacuum to capture and / or immobilize a solid deposit at a location internal to a subject. Such configurations may be useful, for example, for removing intact kidney stones small enough to pass through the ureter. In some cases, the devices further include an ablation instrument. Such devices may be useful, for example, for ablating larger solid deposits into a plurality of smaller particles at a location internal to the subject (e.g., ablating kidney stones that are too large to pass through the ureter). In some cases, the vacuum created by the devices is used to remove the plurality of smaller particles from the location internal to the subject.

Implementations of the present disclosure generally relate to medical aspiration devices and their methods of use. In some cases, the devices are configured to create a vacuum to capture and / or immobilize a solid deposit at a location internal to a subject. Such configurations may be useful, for example, for removing intact kidney stones small enough to pass through the ureter. In some cases, the devices further include an ablation instrument. Such devices may be useful, for example, for ablating larger solid deposits into a plurality of smaller particles at a location internal to the subject (e.g., ablating kidney stones that are too large to pass through the ureter). In some cases, the vacuum created by the devices is used to remove the plurality of smaller particles from the location internal to the subject.

The invention belongs to the technical field of kidney stone examination. The invention relates to the field of biotechnology, in particular to application of Allobacter as a microbial marker in preparation of a product for diagnosing kidney calcium oxalate calculus, and particularly relates to application of Allobacter as a microbial marker in preparation of a product for diagnosing kidney calcium oxalate calculus. According to the present invention, the research results show that the Allobacter microorganism can be adopted as the potential biomarker for the diagnosis of the kidney calcium oxalate calculus; the scheme can be used for assisting clinical diagnosis of kidney calcium oxalate calculi and screening of high-risk people, and a brand new thought and an effective means are provided for accurate prevention and control of kidney calcium oxalate calculi. The invention provides a novel and noninvasive microbial marker which is used for auxiliary diagnosis of kidney stone. The marker has good detection specificity and high sensitivity, can effectively reflect the occurrence and development conditions of calcium oxalate calculi, is expected to replace a traditional imaging examination method, realizes simple, convenient and rapid diagnosis of urinary calculi, and has good application prospects and values.

The present invention relates to a multivitamin formulation for reducing the risk of kidney stone formation. Such formulations comprise a reduction or elimination in one or more of one or more of vitamin C, vitamin D3, and / or calcium. The multivitamin formulations of the present invention may further include magnesium citrate, inositol hexaphosphate (IP-6), and / or banana stem extract. Also provided is a method for customizing a multivitamin formulation for reducing the risk of kidney stone formation in a patient. The method comprises assessing one or more criteria selected from history and physical exam, serum studies, spot urine parameters or 24 hour urine collections. Based on this assessment, a custom multivitamin formulation can be administered in accordance with the formulations described herein.

The utility model belongs to the CT enhancement scanning auxiliary device field especially, and it is more particularly to a urinary system abdominal compression enhancement CT scanning pressurization restraint device. The technical includes the restraint band, the restraint band front side inner wall is provided with the pressurization piece, and the pressurization piece is oval structure, and the restraint band front side outer wall is provided with the adjusting assembly for driving pressurization piece left and right movement. The utility model discloses through the cooperation of restraint band and pressurization piece, is convenient for when scanning and places pressurization piece in patient abdominal side bilateral sacroiliac joint level, delays contrast agent excretion, makes contrast agent temporarily in ureter renal pelvis calyx, renal pelvis calyx expansion, and then utilizes post-processing technology to make contrast agent and lesion show good contrast, thereby benefit the position of judging stone and the relationship with renal pelvis, calyx, ensure the accurate detection and evaluation of kidney stone, also convenient for adjusting the position of pressurization piece according to different patients during use, make the stability and accuracy of scanning result higher while making the applicability higher.

The invention discloses a siRNA (small interfering Ribonucleic Acid) for inhibiting the gene expression of a urate transporter 1 (URAT1) in a human body cell, and particularly discloses a siRNA (small interfering Ribonucleic Acid) for inhibiting the gene expression of the URAT1 in the human body cell. According to the invention, a plurality of siRNAs which can be used for inhibiting URAT1 expression are screened, and on the basis, proper modification is carried out to improve the silence ability of a target. The medicine taking the siRNA as the activity is expected to be clinically applied to prevention and treatment of diseases such as gout, hyperuricemia, gouty arthritis, kidney stone and the like related to URAT1 targets.

Devices for guiding an instrument into a body of a patient, at a targeted point of entry and along an insertion path at a targeted insertion angle, are described herein, such as a guide for an access needle in a PCNL procedure for accessing the kidney to remove kidney stones. The devices include base component aligned with a point of entry, and a guide assembly which cooperates with the base component to allow an instrument to be aligned and fixed at various circumferential and vertical angles. The devices and methods allow a medical professional to accurately and stably guide an instrument at a targeted point and angle and to a desired depth, while minimizing the exposure to radiation used to image the insertion path.

A laser-based system and method for treating kidney stones. The system may include a laser configured to emit pulsed laser energy and a controller configured to control the laser. The laser may be modulated to operate in one of the following modes of operation: pulverization, fragmentation, or reduced backward movement. One or more of these modes of operation may include pulses composed of subpulses.

The invention discloses application of calycosin-7-glucoside in a medicine for treating kidney stone, and the calycosin-7-glucoside can prevent / treat kidney stone, so that the calycosin-7-glucoside can be used for preparing the medicine for treating kidney stone and the medicine for preventing kidney stone formation, and a new medicine and a new treatment thought are provided for treating or preventing calcium oxalate kidney stone diseases.

To provide novel agents for preventing and / or treating kidney stones.SOLUTION: Provided is an agent for inhibiting the growth of kidney stones, comprising a peptide containing an amino acid sequence that satisfies the following conditions, or a nucleic acid encoding the peptide: (1) an amino acid sequence of 20 or more consecutive amino acids in a region consisting of an SRCR1 domain and a hinge region of apoptosis inhibitor of macrophage (AIM); and (2) (the number of aspartic acid and glutamic acid in the amino acid sequence) - (the number of arginine and lysine in the amino acid sequence)≥5.SELECTED DRAWING: None

The ganoderma lucidum and mesona chinensis preparation is prepared from 10-100 g of ganoderma lucidum, 10-100 g of mesona chinensis (mesona chinensis), 10-100 g of rhizoma polygonati, 10-100 g of astragalus membranaceus, 10-100 g of dandelion, 10-100 g of herba cepbalanoplosis segeti, 10-100 g of fructus gardeniae, 10-100 g of honeysuckle, 10-100 g of pilea cavaleriei, 10-100 g of centipede, 10-100 g of cudrania cochinchinensis, 4-40 g of embroidery needle, 4-40 g of bitter The preparation can clear away heat and toxic materials, induce diuresis to alleviate edema, improve the immunity of a human body, effectively reduce serum creatinine, uric acid, blood pressure and blood sugar, improve the immunity of the human body, improve the immunity of the human body, reduce the toxic and side effects of the human body, reduce the toxic and side effects of the human body, reduce the toxic and side effects of the human body, and reduce the toxic and side effects of the human body. The traditional Chinese medicine composition has good treatment effects on uremia, nephritis, renal cyst, kidney stone, hepatitis B, cirrhosis, liver ascites, insomnia, asthma, pharyngitis, cough, cancerous diseases and cardia-cerebrovascular diseases.